Article info

Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting

Authors

  1. Correspondence to Professor Yoshiya Tanaka, First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu 807-8555, Japan; tanaka{at}med.uoeh-u.ac.jp
View Full Text

Citation

Miyazaki Y, Nakano K, Nakayamada S, et al
Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting

Publication history

  • Received December 12, 2020
  • Revised March 22, 2021
  • Accepted March 25, 2021
  • First published April 7, 2021.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.